Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cinnamic acid (β-Phenylacrylic acid) 在癌症干预中具有潜在的应用价值,对胶质母细胞瘤,黑色素瘤,前列腺癌,肺癌细胞的IC50=1-4.5 mM。
产品描述 | Cinnamic acid (β-Phenylacrylic acid) has potential use in cancer intervention,The concentration causing a 50% reduction of cell proliferation (IC50) ranged from 1 to 4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells. |
体内活性 | Oinnamic acid?exerts anti-diabetic activity by improving glucose tolerance in vivo and stimulating insulin secretion in vitro. |
动物实验 | Non-obese type 2 diabetes was developed by injecting 90 mg/kg streptozotocin in 2-day-old Wistar pups. Cinnamic acid and cinnamaldehyde were administered orally to diabetic rats for assessing acute blood glucose lowering effect and improvement of glucose tolerance. Additionally, insulin secretory activity of cinnamic acid and cinnamaldehyde was evaluated in isolated mice islets. Cinnamic acid, but not cinnamaldehyde, decreased blood glucose levels in diabetic rats in a time- and dose-dependent manner. Oral administration of cinnamic acid with 5 and 10 mg/kg doses to diabetic rats improved glucose tolerance in a dose-dependent manner. The improvement by 10 mg/kg cinnamic acid was comparable to that of standard drug glibenclamide (5 mg/kg). |
别名 | 3-Phenylacrylic acid, β-Phenylacrylic acid, 肉桂酸 |
分子量 | 148.16 |
分子式 | C9H8O2 |
CAS No. | 621-82-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 50 mg/mL (337.47 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol | 1 mM | 6.7495 mL | 33.7473 mL | 67.4946 mL | 168.7365 mL |
5 mM | 1.3499 mL | 6.7495 mL | 13.4989 mL | 33.7473 mL | |
10 mM | 0.6749 mL | 3.3747 mL | 6.7495 mL | 16.8737 mL | |
20 mM | 0.3375 mL | 1.6874 mL | 3.3747 mL | 8.4368 mL | |
50 mM | 0.135 mL | 0.6749 mL | 1.3499 mL | 3.3747 mL | |
100 mM | 0.0675 mL | 0.3375 mL | 0.6749 mL | 1.6874 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Cinnamic acid 621-82-9 Metabolism Endogenous Metabolite inhibit b-Phenylacrylic acid 3-Phenylacrylic acid beta-Phenylacrylic acid β-Phenylacrylic acid Inhibitor 肉桂酸 inhibitor